Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
241-255 of 474
Modern Approaches to Long-Term Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerModern Approaches to Long-Term Metastatic Breast Cancer Care
Charles Turck, PharmD, BCPS, BCCCP
Adam Brufsky, MD, PhD
DESTINY-Breast11 and Neoadjuvant Care in HER2-Positive Breast Cancer
On the Frontlines of Metastatic Breast CancerDESTINY-Breast11 and Neoadjuvant Care in HER2-Positive Breast Cancer
Jules Cohen, MD
Exploring T-DXd in HER2-Positive Breast Cancer Treatment
On the Frontlines of Metastatic Breast CancerExploring T-DXd in HER2-Positive Breast Cancer Treatment
Charles Turck, PharmD, BCPS, BCCCP
Jules Cohen, MD
The Metabolic Roots of Early-Onset Colorectal Cancer
Project Oncology®The Metabolic Roots of Early-Onset Colorectal Cancer
Addressing Unmet Needs in Metastatic Uveal Melanoma
CME/CEAddressing Unmet Needs in Metastatic Uveal Melanoma
Marlana Orloff, MD
Gregory Daniels, MD, PhD
Jesse Keller, MD
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
CME/CEPatients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
Ryan D. Cassaday, MD
Daniel J. DeAngelo, MD, PhD
- advertisement
Exercise in CRC Survivors: A Closer Look at Biomarker Effects
Project Oncology®Exercise in CRC Survivors: A Closer Look at Biomarker Effects
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Seth Wander, MD, PhD
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Pavani Chalasani, MD, MPH
Timothy Yap, MBBS, PhD, FRCP
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Alexandria May, PharmD, BCPS
Nicholas Whipple, MD, MPH
Tracking Tumor Resistance in Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerTracking Tumor Resistance in Metastatic Breast Cancer Care
Ryan Quigley
Megan Kruse, MD
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstractsOptimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Marlene Mimi Maeusli, PhD.
- advertisement
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Ryan Quigley
Kathrin M. Bernt, MD
Rushabh Mehta, BS
Fatemeh Alikarami
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
A.J. Gelderblom, MD, PhD
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
A.J. Gelderblom, MD, PhD